PDF herunterladen
Arzneimittelforschung 2008; 58(1): 24-28
DOI: 10.1055/s-0031-1296462
Antiallergic Drugs · Antiasthmatics · Antitussives · Bronchodilators · Bronchosecretogogues · Mucolytics
Editio Cantor Verlag Aulendorf (Germany)

Long-term Effect of the β2-Receptor Agonist Procaterol on Daily Life Performance and Exercise Capacity in Patients with Stable Chronic Obstructive Pulmonary Disease

Clinical study with special reference to health-related quality of life and activities of daily living
Takanobu Shioya
1   Department of Physical Therapy, Akita University School of Health Sciences, Akita, Japan
,
Masahiro Satake
1   Department of Physical Therapy, Akita University School of Health Sciences, Akita, Japan
,
Kazuhiro Sato
2   The Second Department of Internal Medicine, Akita University School of Medicine, Akita, Japan
4   Department of Pulmonary Medicine, Akita City General Hospital, Akita, Japan
,
Masa-aki Sano
2   The Second Department of Internal Medicine, Akita University School of Medicine, Akita, Japan
,
Keiyu Sugawara
3   Department of Rehabilitation, Akita City General Hospital, Akita, Japan
,
Hitomi Takahashi
3   Department of Rehabilitation, Akita City General Hospital, Akita, Japan
,
Mitsunobu Honma
4   Department of Pulmonary Medicine, Akita City General Hospital, Akita, Japan
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
15. Dezember 2011 (online)

    Lizenzen und Reprints

Summary

The present study was undertaken to evaluate the long-term effect of procaterol hydrochloride (CAS 62929-91-3, Meptin™), a third generation β2-receptor agonist on lung function, exercise capacity, health-related quality of life (HRQOL) and activities of daily living (ALDs) in patients with stable chronic obstructive pulmonary disease (COPD). Twenty patients were randomly assigned to the procaterol group or to the control group, who received oxitropium bromide (CAS 30286-75-0), an anticholinergic agent. Procaterol was inhaled three times a day at a dose of 20 µg, while oxitropium was inhaled three times a day at a dose of 200 µg. The subjects were evaluated based on spirometry, exercise capacity, the Borg Scale, HRQOL, and ADLs before and after 12, 24 and 52 weeks of therapy. The values of forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), total lung capacity (TLC), functional residual capacity (FRC), residual volume (RV), maximal inspiratory pressure (PImax), and maximal expiratory pressure (PEmax) were significantly improved at 12, 24 and 52 weeks compared with baseline values in the procaterol group (p<0.05, p<0.01), while these values did not differ from baseline values at any point in the oxitropium group (p>0.05). Additionally, 6-min walking distances and Borg Scale values showed significant improvement at 12, 24 and 52 weeks compared with baseline values in the procaterol group (p<0.05, p<0.01), but did not significantly differ from baseline values in the oxitropium group at any point (p>0.05). Likewise, the scores for dyspnea, fatigue, emotional function, mastery, total scores and ADLs were significantly higher at 12, 24 and 52 weeks compared with the baseline values in the procaterol group (p<0.05, p<0.01), but did not differ at any point in the oxitropium group (p>0.05). These results suggest the effectiveness of long-term regular bronchodilator therapy with the β2-receptor agonist procaterol in patients with stable COPD.

Key words

β2-Receptor agonists - CAS 62929-91-3 - Meptin™ - Procaterol hydrochloride, activities of daily living, effects on lung function, - exercise capacity, health-related quality of life
 

  • References

  • 1 Agusti AGN. COPD a multicomponent disease: implications for management. Respir Med. 2005; 99: 670-682
    CrossrefPubMedGoogle Scholar
  • 2 Currie GP, Rossiter C, Miles SA et al. Effects of tiotropium and other long acting bronchodilators in chronic obstructive pulmonary disease. Pulm Pharm Ther. 2006; 19: 112-119
    CrossrefPubMedGoogle Scholar
  • 3 Nocturnal Oxygen Therapy Trial Group Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Ann Int Med. 1980; 93: 391-398
    PubMedGoogle Scholar
  • 4 Medical Research Council Working Party Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonare complicating chronic bronchitis and emphysema. Lancet. 1981; 1: 681-686
    PubMedGoogle Scholar
  • 5 Bosse R, Sparrow D, Rose CL et al. Longitudinal effect of age and smoking cessation on pulmonary function. Am Rev Respir Dis. 1981; 123: 378-381
    PubMedGoogle Scholar
  • 6 Anthoniesen NR, Connett JE, Murray RP. Smoking and lung function of lung health study participants after 11 years. Am J Respir Crit Care Med. 2002; 166: 675-679
    CrossrefPubMedGoogle Scholar
  • 7 Yabuuchi Y, Yamahsita S, Tei S-S. Pharmacological studies of OPC-2009, a newly synthesized selective beta adrenoceptor stimulant, in the bronchomotor and cardiovascular system of the anaesthetized dog. J Pharmacol Exp Ther. 1977; 202: 326-336
    PubMedGoogle Scholar
  • 8 Mirza ZN, Arakawa Tokuyama K et al. al. Inhaled procaterol inhibits histamine-induced airflow obstruction and microvascular leakage in guinea pig airways with allergic inflammation. Clin Exp Allergy. 1998; 28: 644-652
    CrossrefPubMedGoogle Scholar
  • 9 American Thoracic Society Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1995; 152: S77-S120
    PubMedGoogle Scholar
  • 10 Saltiel E, Wolfe R. Focus on procaterol. A ß2-selective adrenergic bronchodilator for use in asthma and other bronchial airway disorders. Hosp Formul. 1994; 29: 621-627
    PubMedGoogle Scholar
  • 11 Mortons SS, Gross NJ, Moriz T et al. Oxitropium bromide, a new anticholinergic bronchodilator. Ann Allergy. 1986; 56: 229-232
    PubMedGoogle Scholar
  • 12 Black LF, Hyatt RE. Maximal respiratory pressures;normal values and relationship to age and sex. Am Rev Respir Dis. 1969; 99: 696-702
    PubMedGoogle Scholar
  • 13 American Thoracic Society Pulmonary rehabilitation. Am Rev Respir Dis. 1999; 159: 1666-1982
    PubMedGoogle Scholar
  • 14 Borg GAV. Psycho-physical bases of perceived exertion. Med Sci Sports Exerc. 1982; 14: 377-381
    PubMedGoogle Scholar
  • 15 Guyatt GH, Berman LB, Townsend M et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987; 42: 773-778
    CrossrefPubMedGoogle Scholar
  • 16 Garrod R, Bestall JC, Paul EA et al. Development and validation of a standardized measure of a activity of daily living in patients with severe COPD: the London Chest Activity of Daily Living Scale (LCADL). Respir Med. 2000; 94: 589-596
    CrossrefPubMedGoogle Scholar
  • 17 Global Initiative for Chronic Obstructive Lung Disease: Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHL-BI/WHO Workshop Report, Updated 2006.
    PubMed
  • 18 Bauer R. Zur Pharmakokologie des Bronchospasmolytikums Oxitropiumbromid. Arzneimittel-Forschung (Drug Research). 1985; 35: 435-440
    PubMedGoogle Scholar
  • 19 Taunecker W. Bronchospasmolytic effect oxitropium bromide following powder inhalation in anaesthetized dogs. Arzneimittel-Forschung (Drug Research). 1988; 38: 1623-1624
    PubMedGoogle Scholar
  • 20 Tashkin DT, Kesten S. Long-term treatment benefits with tiotropium in COPD patients with and without short-term bronchodilator responses. Chest. 2003; 123: 1441-1449
    CrossrefPubMedGoogle Scholar
  • 21 Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci. 1993; 52: 521-528
    CrossrefPubMedGoogle Scholar
  • 22 Uzuki M, Yamakage M, Fujimura N et al. Preferable inotropic action procaterol, a potent bronchodilator, on impaired diaphragmatic contractility in an intraabdominal septic model. J Anesth. 2006; 20: 145-148
    CrossrefPubMedGoogle Scholar
  • 23 Mazza JA, Tashkin DP, Reed CE. Evaluation of procaterol and albuterol (salbutamol) aerosol in the treatment of asthma. Ann Allergy. 1992; 68: 267-273
    PubMedGoogle Scholar
  • 24 Kume H. Clinical use of ß2-adrenergic receptor agonists based on their intrinsic efficacy. Allergol Int. 2005; 54: 89-97
    CrossrefPubMedGoogle Scholar
  • 25 Man WD, Mustfa N, Nikoletou D et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax. 2004; 59: 471-476
    CrossrefPubMedGoogle Scholar